Search - tctmd.com

Displaying 661 - 680 of 697

Sort: Relevancy | Date

News Conference News ACC 2016

Statin Intolerance and FH: GAUSS-3 Finds Benefit With Evolocumab, While Another Study Exposes Lifetime Risks of FH

Michael O'Riordan

April 03, 2016

News Conference News ACC 2016

HOPE-3: Reducing LDL Cholesterol Improves Outcomes in Intermediate-Risk Patients, but BP-Lowering Does Not

Michael O'Riordan

April 02, 2016

News Daily News

ACC 更新降低低密度脂蛋白胆固醇降低的建议，为依折麦布和 PCSK9 抑制剂留出了空间

Michael O'Riordan

April 02, 2016

News Daily News

ACC Updates LDL-Cholesterol Lowering Recommendations, Making Room for Ezetimibe and PCSK9 Inhibitors

Michael O'Riordan

April 02, 2016

News Daily News

ACC actualiza las recomendaciones para bajar el colesterol LBD, abriendo un espacio para el uso de Ezetimibe y de los inhibidores de PCSK9

Michael O'Riordan

April 02, 2016

News Daily News

研究认为有数据支持针对患者风险而非 LDL 胆固醇目标进行治疗

Michael O'Riordan

February 15, 2016

News Daily News

Según un Informe los Datos Avalan Tratar el Riesgo de los Pacientes No las Dianas de Colesterol LBD

Michael O'Riordan

February 15, 2016

News Daily News

Data Support Treating Patient Risk, Not LDL Cholesterol Targets, Paper Argues

Michael O'Riordan

February 15, 2016

News Daily News

他汀类药物可能会保护无症状 PAD 患者免于死亡、心血管事件

Caitlin E. Cox

February 08, 2016

News Daily News

Statins Possibly Protect Against Death, CV Events in Asymptomatic PAD PatientsLas Estatinas Podrían Proteger frente a la Muerte y los Episodios CV en Pacientes EAP Asintomáticos

Caitlin E. Cox

February 08, 2016

News Daily News

Statins Possibly Protect Against Death, CV Events in Asymptomatic PAD Patients

Caitlin E. Cox

February 08, 2016

News Features

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Michael O'Riordan

January 25, 2016

News Daily News

USPSTF Issues Preliminary Recommendations on Statin Use in Primary Prevention

Michael O'Riordan

January 12, 2016

News Daily News

心梗后、PCI 后以及 CAD 患者的他汀类药物绩效指标发生修订

Michael O'Riordan

December 20, 2015

News Daily News

Revisión de las Métricas de Rendimiento para el Uso de Estatinas Post-IM, Post-PCI en Pacientes EAC

Michael O'Riordan

December 20, 2015

News Daily News

Performance Metrics Revised for Statins Post-MI, After PCI, and in CAD Patients

Michael O'Riordan

December 20, 2015

News Daily News

ACC, AHA Risk-Based Approach Remains Best Method for Statin Allocation in Primary Prevention

Michael O'Riordan

December 13, 2015

News Daily News

与他汀类药物相关的负面新闻与停药和心血管风险增加有关

Michael O'Riordan

December 02, 2015

News Daily News

Negative Statin-Related News Linked With Drug Discontinuation, Increased CV Risk

Michael O'Riordan

December 02, 2015

News Conference News AHA 2015

Degree of LDL Cholesterol-Lowering on High-Intensity Rosuvastatin Determines Clinical Impact

Todd Neale

November 12, 2015

Advertisement

Statin Intolerance and FH: GAUSS-3 Finds Benefit With Evolocumab, While Another Study Exposes Lifetime Risks of FH

HOPE-3: Reducing LDL Cholesterol Improves Outcomes in Intermediate-Risk Patients, but BP-Lowering Does Not

ACC 更新降低低密度脂蛋白胆固醇降低的建议，为依折麦布和 PCSK9 抑制剂留出了空间

ACC Updates LDL-Cholesterol Lowering Recommendations, Making Room for Ezetimibe and PCSK9 Inhibitors

ACC actualiza las recomendaciones para bajar el colesterol LBD, abriendo un espacio para el uso de Ezetimibe y de los inhibidores de PCSK9

研究认为有数据支持针对患者风险而非 LDL 胆固醇目标进行治疗

Según un Informe los Datos Avalan Tratar el Riesgo de los Pacientes No las Dianas de Colesterol LBD

Data Support Treating Patient Risk, Not LDL Cholesterol Targets, Paper Argues

他汀类药物可能会保护无症状 PAD 患者免于死亡、心血管事件

Statins Possibly Protect Against Death, CV Events in Asymptomatic PAD PatientsLas Estatinas Podrían Proteger frente a la Muerte y los Episodios CV en Pacientes EAP Asintomáticos

Statins Possibly Protect Against Death, CV Events in Asymptomatic PAD Patients

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

USPSTF Issues Preliminary Recommendations on Statin Use in Primary Prevention

心梗后、PCI 后以及 CAD 患者的他汀类药物绩效指标发生修订

Revisión de las Métricas de Rendimiento para el Uso de Estatinas Post-IM, Post-PCI en Pacientes EAC

Performance Metrics Revised for Statins Post-MI, After PCI, and in CAD Patients

ACC, AHA Risk-Based Approach Remains Best Method for Statin Allocation in Primary Prevention

与他汀类药物相关的负面新闻与停药和心血管风险增加有关

Negative Statin-Related News Linked With Drug Discontinuation, Increased CV Risk

Degree of LDL Cholesterol-Lowering on High-Intensity Rosuvastatin Determines Clinical Impact

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content